Definitive Healthcare earnings release, August 10, 2026

Definitive Healthcare Corp. (DH) · Form 8-K, Item 2.02 · Filed · SEC filing

Definitive Healthcare Reports Financial Results for Second Quarter 2026

Second Quarter Revenue Within Guidance Range; Profit Surpasses Expectations

Framingham, MA (August 10, 2026) – Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare market data and analytics, today announced financial results for the quarter ended June 30, 2026.

Second Quarter 2026 Financial Highlights:

• Revenue was $55.2 million, a decrease of 9% from $60.8 million in Q2 2025.

• Net Loss was $(7.5) million, or (14)% of revenue, compared to $(9.3) million, or (15)% of revenue in Q2 2025.

• Adjusted Net Income was $7.5 million, compared to $9.7 million in Q2 2025.

• Adjusted EBITDA was $14.6 million, or 26% of revenue, compared to $18.7 million, or 31% of revenue in Q2 2025.

• Cash Flow from Operations was $11.5 million in the quarter.

• Unlevered Free Cash Flow was $11.6 million in the quarter.

“Definitive Healthcare delivered another quarter in line with or above our guidance ranges, reflecting continued discipline alongside targeted investment in our growth priorities," said Kevin Coop, CEO of Definitive Healthcare. "We're encouraged by our second consecutive quarter of year-over-year improvement in net dollar retention, strong win-back momentum across our end markets, and the launch of Turbo, our new AI-powered healthcare intelligence platform, which marks a significant milestone in our innovation strategy. We remain confident that our focus on data quality and customer success is the right path to return to sustained, predictable growth, while continuing to generate strong profitability and cash flow.”

Recent Business and Operating Highlights:

Customer Wins

In the second quarter, Definitive Healthcare continued to win new logos and expansion opportunities across all end-markets, by providing the data, insights and integrations that drive their critical business use cases. Customer wins for the quarter included:

• A diversified-business customer returned to Definitive Healthcare in a six-figure, three-year win-back enterprise agreement. This win reinforces a recurring theme: customers who believe a lower-cost alternative will be “good enough” ultimately recognize that the cost of an inferior dataset outweighs the savings, validating the business value our data and products deliver and reaffirming that our focus on data quality and service, rather than price, is the right path forward.

• One long-standing population-intelligence customer expanded from an initial test into a total activation commitment of several hundred thousand dollars, illustrating that activation growth is now being driven not only by new direct customers but also by rising adoption and spend across our agency ecosystem, which gives us a broader, more scalable path forward.

Business Outlook

Based on information as of August 10, 2026, the Company is issuing the following financial guidance.

Third Quarter 2026:

• Revenue is expected to be in the range of $54.0 – $55.0 million.

• Adjusted Operating Income is expected to be in the range of $10.5 – $11.5 million.

• Adjusted EBITDA is expected to be in the range of $13.5 – $14.5 million, and 25% – 27% adjusted EBITDA Margin.

• Adjusted Net Income is expected to be $5.5 – $6.5 million.

• Adjusted Net Income Per Diluted Share is expected to be $0.04 to $0.05 per share on approximately 145.1 million weighted-average shares outstanding.

Full Year 2026:

• Revenue is expected to be in the range of $220.0 – $222.0 million.

• Adjusted Operating Income is expected to be in the range of $45.5 – $47.5 million.

• Adjusted EBITDA is expected to be in the range of $57.0 – $59.0 million, and 26% – 27% adjusted EBITDA Margin.

• Adjusted Net Income is expected to be $27.0 – $29.0 million.

• Adjusted Net Income Per Diluted Share is expected to be $0.18 to $0.20 per share on approximately 144.6 million weighted-average shares outstanding.

We do not provide a quantitative reconciliation of the forward-looking non-GAAP financial measures included in this press release to the most directly comparable GAAP measures due to the high variability and difficulty in predicting certain items excluded from these non-GAAP financial measures; in particular, the effects of equity-based compensation expense, taxes and amounts under the tax receivable agreement, deferred tax assets and deferred tax liabilities, and transaction, integration, and restructuring expenses. We expect the variability of these excluded items may have a significant and potentially unpredictable impact on our future GAAP financial results.

Conference Call Information

Definitive Healthcare will host a conference call today, August 10, 2026, at 5:00 p.m. (Eastern Time) to discuss the Company's full financial results and current business outlook. Participants may access the call at 1-877-358-7298 or 1-848-488-9244. Shortly after the conclusion of the call, a replay of this conference call will be available through September 9, 2026, at 1-800-645-7964 or 1-757-849-6722. The replay passcode is 1765#. A live audio webcast of the event will be available on Definitive Healthcare’s Investor Relations website at ir.definitivehc.com/.

About Definitive Healthcare

Definitive Healthcare is a data and analytics company focused on the business side of healthcare. The healthcare market is complex — our data makes it clearer. We cut through the noise to deliver the insights that healthcare organizations and companies need to make smarter, faster, more strategic decisions. Because when our customers succeed, healthcare gets better for everyone. Learn more at definitivehc.com.

Financial statements

Income Statement

bswackhamer@definitivehc.com (in thousands, except share amounts and per share data; unaudited)

Definitive Healthcare Corp. – Condensed Consolidated Statements of Operations – Three Months Ended June 30, – 2026Three Months Ended June 30, – 2026Definitive Healthcare Corp. – Condensed Consolidated Statements of Operations – Three Months Ended June 30, – 2025Three Months Ended June 30, – 2025Definitive Healthcare Corp. – Condensed Consolidated Statements of Operations – Six Months Ended June 30, – 2026Six Months Ended June 30, – 2026Definitive Healthcare Corp. – Condensed Consolidated Statements of Operations – Six Months Ended June 30, – 2025Six Months Ended June 30, – 2025
Revenue55,19560,750111,124119,941
Cost of revenue:Cost of revenue exclusive of amortization (1)9,4188,80018,77318,941
Cost of revenue:Amortization5,2365,33710,16010,627
Cost of revenue:Gross profit40,54146,61382,19190,373
Operating expenses:Sales and marketing (1)19,15820,46938,73641,122
Operating expenses:Product development (1)6,7567,96813,25517,269
Operating expenses:General and administrative (1)10,80612,67322,89024,942
Operating expenses:Depreciation and amortization8,5429,00116,86717,528
Operating expenses:Transaction, integration, and restructuring expenses2,0276721,2621,937
Operating expenses:Goodwill impairment197,219176,531
Operating expenses:Total operating expenses47,28950,783290,229279,329
Operating expenses:Loss from operations-6,748-4,170-208,038-188,956
Other income, netInterest expense, net-1,375-1,241-2,707-1,622
Other income, netOther income (expense), net326-3,3987,15915,790
Other income, netTotal other (expense) income, net-1,049-4,6394,45214,168
Other income, netNet loss before income taxes-7,797-8,809-203,586-174,788
Other income, netBenefit from (provision for) income taxes345-4563,78010,430
Other income, netNet loss-7,452-9,265-199,806-164,358
Other income, netLess: Net loss attributable to noncontrolling interests-2,030-1,714-55,763-49,579
Other income, netNet loss attributable to Definitive Healthcare Corp.-5,422-7,551-144,043-114,779
Net loss per share of Class A common stock:Basic and diluted-0.05-0.07-1.37-1.05
Weighted average Class A common stock outstanding:Basic and diluted105,810,516106,815,740105,245,928109,782,640
(1) Amounts include equity-based compensation expense as follows:Cost of revenue94180176340
(1) Amounts include equity-based compensation expense as follows:Sales and marketing1,0531,0382,0042,217
(1) Amounts include equity-based compensation expense as follows:Product development2941,4166693,155
(1) Amounts include equity-based compensation expense as follows:General and administrative3,8134,3467,6258,587
(1) Amounts include equity-based compensation expense as follows:Total equity-based compensation expense5,2546,98010,47414,299

Income Statement

Reconciliations of Non-GAAP Financial Measures to Closest GAAP Equivalent (in thousands, except share and per share amounts; unaudited)

Reconciliation of GAAP Net Loss to Adjusted Net Income and – GAAP Operating Loss to Adjusted Operating Income – Three Months Ended June 30, – 2026Reconciliation of GAAP Net Loss to Adjusted Net Income and – GAAP Operating Loss to Adjusted Operating Income – Three Months Ended June 30, – 2025Reconciliation of GAAP Net Loss to Adjusted Net Income and – GAAP Operating Loss to Adjusted Operating Income – Six Months Ended June 30, – 2026Reconciliation of GAAP Net Loss to Adjusted Net Income and – GAAP Operating Loss to Adjusted Operating Income – Six Months Ended June 30, – 2025
Net loss-7,452-9,265-199,806-164,358
Add: Income tax (benefit) provision-345456-3,780-10,430
Add: Interest expense, net1,3751,2412,7071,622
Add: Loss on partial extinguishment from debt507
Add: Other (income) expense, net-3263,398-7,159-16,297
Loss from operations-6,748-4,170-208,038-188,956
Add: Amortization of intangible assets acquired through business combinations10,99711,32121,80522,410
Add: Equity-based compensation5,2546,98010,47414,299
Add: Transaction, integration, and restructuring expenses2,0276721,2621,937
Add: Goodwill impairment charge197,219176,531
Add: Other non-core items3108362,0031,396
Adjusted Operating Income11,84015,63924,72527,617
Less: Interest expense, net-1,375-1,241-2,707-1,622
Less: Recurring income tax benefit (provision)345-456218-104
Less: Foreign currency gain (loss)262-497574-1,466
Less: Tax impacts of adjustments to net loss-3,559-3,769-6,780-7,777
Adjusted Net Income7,5139,67616,03016,648
Shares for Adjusted Net Income Per Diluted Share (a)143,964,049145,675,930143,459,263148,721,063
Adjusted Net Income Per Share0.050.070.110.11

Income Statement

Reconciliations of Non-GAAP Financial Measures to Closest GAAP Equivalent (in thousands, except percentages; unaudited)

Reconciliation of GAAP Gross Profit and Margin to Adjusted Gross Profit and Margin – Three Months Ended June 30, – 2026 – AmountReconciliation of GAAP Gross Profit and Margin to Adjusted Gross Profit and Margin – Three Months Ended June 30, – 2026 – % of RevenueReconciliation of GAAP Gross Profit and Margin to Adjusted Gross Profit and Margin – Three Months Ended June 30, – 2025 – AmountReconciliation of GAAP Gross Profit and Margin to Adjusted Gross Profit and Margin – Three Months Ended June 30, – 2025 – % of RevenueReconciliation of GAAP Gross Profit and Margin to Adjusted Gross Profit and Margin – Six Months Ended June 30, – 2026 – AmountReconciliation of GAAP Gross Profit and Margin to Adjusted Gross Profit and Margin – Six Months Ended June 30, – 2026 – % of RevenueReconciliation of GAAP Gross Profit and Margin to Adjusted Gross Profit and Margin – Six Months Ended June 30, – 2025 – AmountReconciliation of GAAP Gross Profit and Margin to Adjusted Gross Profit and Margin – Six Months Ended June 30, – 2025 – % of Revenue
Reported gross profit and margin40,54173.0%46,61377.0%82,19174.0%90,37375.0%
Amortization of intangible assets acquired through business combinations3,5256.0%3,1885.0%7,0126.0%6,3415.0%
Equity compensation costs940.0%1800.0%1760.0%3400.0%
Adjusted gross profit and margin44,16080.0%49,98182.0%89,37980.0%97,05481.0%

Income Statement

Reconciliations of Non-GAAP Financial Measures to Closest GAAP Equivalent (in thousands, except percentages; unaudited)

Reconciliation of GAAP Net Loss and Margin to Adjusted EBITDA and Margin – Three Months Ended June 30, – 2026 – AmountReconciliation of GAAP Net Loss and Margin to Adjusted EBITDA and Margin – Three Months Ended June 30, – 2026 – % of RevenueReconciliation of GAAP Net Loss and Margin to Adjusted EBITDA and Margin – Three Months Ended June 30, – 2025 – AmountReconciliation of GAAP Net Loss and Margin to Adjusted EBITDA and Margin – Three Months Ended June 30, – 2025 – % of RevenueReconciliation of GAAP Net Loss and Margin to Adjusted EBITDA and Margin – Six Months Ended June 30, – 2026 – AmountReconciliation of GAAP Net Loss and Margin to Adjusted EBITDA and Margin – Six Months Ended June 30, – 2026 – % of RevenueReconciliation of GAAP Net Loss and Margin to Adjusted EBITDA and Margin – Six Months Ended June 30, – 2025 – AmountReconciliation of GAAP Net Loss and Margin to Adjusted EBITDA and Margin – Six Months Ended June 30, – 2025 – % of Revenue
Net loss and margin-7,452)%-9,265)%-199,806)%-164,358)%
Interest expense, net1,3752.0%1,2412.0%2,7072.0%1,6221.0%
(Benefit from) provision for income taxes-345)%4561.0%-3,780)%-10,430)%
Loss on partial extinguishment of debt0.0%0.0%0.0%5070.0%
Depreciation & amortization13,77825.0%14,33824.0%27,02724.0%28,15523.0%
EBITDA and margin7,35613.0%6,77011.0%-173,852)%-144,504)%
Other income, net (a)-326)%3,3986.0%-7,159)%-16,297)%
Equity-based compensation (b)5,25410.0%6,98011.0%10,4749.0%14,29912.0%

Balance Sheet

bswackhamer@definitivehc.com (in thousands, except number of shares and par value; unaudited)

Definitive Healthcare Corp. – Condensed Consolidated Balance Sheets – June 30, 2026
Current assets:Cash and cash equivalents170,866
Current assets:Short-term investments12,729
Current assets:Accounts receivable, net30,970
Current assets:Prepaid expenses and other assets13,343
Current assets:Deferred contract costs12,190
Current assets:Total current assets240,098
Current assets:Property and equipment, net14,753
Current assets:Operating lease right-of-use assets, net4,216
Current assets:Other assets3,277
Current assets:Deferred contract costs11,764
Current assets:Intangible assets, net222,724
Current assets:Total assets496,832
Current liabilities:Accounts payable4,531
Current liabilities:Accrued expenses and other liabilities23,787
Current liabilities:Deferred revenue89,342
Current liabilities:Term loan8,750
Current liabilities:Operating lease liabilities2,654
Current liabilities:Total current liabilities129,064
Long term liabilities:Term loan151,885
Long term liabilities:Operating lease liabilities3,767
Long term liabilities:Tax Receivable Agreement liability12,034
Long term liabilities:Deferred tax liabilities11,072
Long term liabilities:Other liabilities1,145
Long term liabilities:Total liabilities308,967
Equity:Class A common stock, par value $0.001, 600,000,000 shares authorized, 106,405,766 and 104,020,957 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively106
Equity:Additional paid-in capital1,069,701
Equity:Accumulated other comprehensive deficit-1,606
Equity:Accumulated deficit-923,549
Equity:Noncontrolling interests43,213
Equity:Total equity187,865
Equity:Total liabilities and equity496,832

Cash Flow

bswackhamer@definitivehc.com (in thousands)

Definitive Healthcare Corp. – Condensed Consolidated Statements of Cash Flows – Three Months Ended June 30, – 2026Definitive Healthcare Corp. – Condensed Consolidated Statements of Cash Flows – Three Months Ended June 30, – 2025Definitive Healthcare Corp. – Condensed Consolidated Statements of Cash Flows – Six Months Ended June 30, – 2026Definitive Healthcare Corp. – Condensed Consolidated Statements of Cash Flows – Six Months Ended June 30, – 2025
Cash flows provided by (used in) operating activities:Net loss-7,452-9,265-199,806-164,358
Adjustments to reconcile net loss to net cash provided by operating activities:Depreciation and amortization1,0708682,0741,459
Adjustments to reconcile net loss to net cash provided by operating activities:Amortization of intangible assets12,70813,47024,95326,696
Adjustments to reconcile net loss to net cash provided by operating activities:Amortization of deferred contract costs3,6993,9887,4397,935
Adjustments to reconcile net loss to net cash provided by operating activities:Equity-based compensation5,2546,98010,47414,299
Adjustments to reconcile net loss to net cash provided by operating activities:Amortization of debt issuance costs181123340249
Adjustments to reconcile net loss to net cash provided by operating activities:Provision for (recovery of) doubtful accounts receivable16-179-192-321
Adjustments to reconcile net loss to net cash provided by operating activities:Loss on partial extinguishment of debt507
Adjustments to reconcile net loss to net cash provided by operating activities:Non-cash restructuring charges183183192
Adjustments to reconcile net loss to net cash provided by operating activities:Goodwill impairment charges197,219176,531
Adjustments to reconcile net loss to net cash provided by operating activities:Tax Receivable Agreement remeasurement-642,901-6,585-17,763
Adjustments to reconcile net loss to net cash provided by operating activities:Changes in fair value of contingent consideration-690
Adjustments to reconcile net loss to net cash provided by operating activities:Deferred income taxes-465398-4,002-10,609
Changes in operating assets and liabilities:Accounts receivable7,9645,52321,22315,874
Changes in operating assets and liabilities:Prepaid expenses and other assets3,0731,453-949-4,230
Changes in operating assets and liabilities:Deferred contract costs-2,919-2,465-5,787-6,259
Changes in operating assets and liabilities:Accounts payable, accrued expenses, and other liabilities-1,964-3,400-13,537-12,145
Changes in operating assets and liabilities:Deferred revenue-9,828-11,091-10,0278,003
Changes in operating assets and liabilities:Net cash provided by operating activities11,4569,30423,02035,370
Cash flows (used in) provided by investing activities:Purchases of property, equipment, and data assets-2,942-2,293-6,144-9,999
Cash flows (used in) provided by investing activities:Purchases of short-term investments-52,065-12,500-64,065
Cash flows (used in) provided by investing activities:Maturities of short-term investments7,84544,19617,326147,447
Cash flows (used in) provided by investing activities:Net cash provided by (used in) investing activities4,903-10,162-1,31873,383

Cash Flow

Reconciliations of Non-GAAP Financial Measures to Closest GAAP Equivalent (in thousands)

Reconciliation of GAAP Operating Cash Flow to Unlevered Free Cash Flow – Three Months Ended June 30, – 2026Reconciliation of GAAP Operating Cash Flow to Unlevered Free Cash Flow – Three Months Ended June 30, – 2025Reconciliation of GAAP Operating Cash Flow to Unlevered Free Cash Flow – Six Months Ended June 30, – 2026Reconciliation of GAAP Operating Cash Flow to Unlevered Free Cash Flow – Six Months Ended June 30, – 2025
Net cash provided by operating activities11,4569,30423,02035,370
Purchases of property, equipment, and data assets-2,942-2,293-6,144-9,999
Interest paid in cash2,4462,9594,9185,201
Transaction, integration, and restructuring expenses paid in cash (a)3446724,4602,435
Other non-core items paid in cash (b)3108363,3201,396
Unlevered Free Cash Flow11,61411,47829,57434,403
(a) Transaction and integration expenses paid in cash primarily represent legal, accounting, and consulting expenses related to our acquisitions. Restructuring expenses paid in cash relate to our restructuring plans. (b) Non-core items paid in cash represent expenses driven by events that are typically by nature one-time, non-operational, and unrelated to our core operations.(a) Transaction and integration expenses paid in cash primarily represent legal, accounting, and consulting expenses related to our acquisitions. Restructuring expenses paid in cash relate to our restructuring plans. (b) Non-core items paid in cash represent expenses driven by events that are typically by nature one-time, non-operational, and unrelated to our core operations.(a) Transaction and integration expenses paid in cash primarily represent legal, accounting, and consulting expenses related to our acquisitions. Restructuring expenses paid in cash relate to our restructuring plans. (b) Non-core items paid in cash represent expenses driven by events that are typically by nature one-time, non-operational, and unrelated to our core operations.
Full release

Forward-Looking Statements... (truncated)or” protection of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be identified by words or phrases written in the future tense and/or preceded by words such as “likely,” “will,” “should,” “may,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “assumes,” “would,” “potentially” or similar words or variations thereof, or the negative thereof, references to future periods, or by the inclusion of forecasts or projections, but these terms are not the exclusive means of identifying such statements. Examples of forward-looking statements include, but are not limited to, statements we make regarding our outlook, financial guidance, the benefits of our healthcare commercial intelligence solutions, our overall future prospects, customer behaviors and use of our solutions, the market, industry and macroeconomic environment, our plans to improve our operational and financial performance and our business, our ability to execute on our plans, customer growth, including our upsell and cross-sell opportunities, and our ability to successfully transition executive leadership.

Forward-looking statements in this press release are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include the following: global geopolitical tension and difficult macroeconomic conditions; actual or potential changes in international, national, regional and local economic, business and financial conditions, including tariffs, sanctions, trade barriers, recessions, fluctuating inflation, high interest rates, volatility in the capital markets and related market uncertainty; our inability to acquire new customers and generate additional revenue from existing customers; our inability to generate sales of subscriptions to our platform or any decline in demand for our platform and the data we offer; the competitiveness of the market in which we operate and our ability to compete effectively; the failure to maintain and improve our platform, or develop new modules or insights for healthcare commercial intelligence; the inability to obtain and maintain accurate, comprehensive or reliable data, which could result in reduced demand for our platform; the loss of our access to our data providers; the failure to respond to advances in healthcare commercial intelligence; an inability to attract new customers and expand subscriptions of current customers; our ability to successfully transition executive leadership; and the possibility that our security measures are breached or unauthorized access to data is otherwise obtained.

Additional factors or events that could cause our actual performance to differ from these forward-looking statements may emerge from time to time, and it is not possible for us to predict all of them. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual financial condition, results of operations, future performance and business may vary in material respects from the performance projected in these forward-looking statements.

For additional discussion of factors that could impact our operational and financial results, refer to our Quarterly Report on Form 10-Q for the three months ended June 30, 2026 that will be filed following this earnings release, as well as our Current Reports on Form 8-K and other subsequent SEC filings, which are or will be available on the Investor Relations page of our website at ir.definitivehc.com and on the U.S. Securities and Exchange Commission ("SEC”) website at www.sec.gov.

All information in this press release speaks only as of the date on which it is made. We undertake no obligation to publicly update this information, whether as a result of new information, future developments or otherwise, except as may be required by law.

Website

Definitive Healthcare intends to use its website as a distribution channel of material company information. Financial and other important information regarding the Company is routinely posted on and accessible through the Company’s website at definitivehc.com. Accordingly, you should monitor the investor relations portion of our website at ir.definitivehc.com in addition to following our press releases, SEC filings, and public conference calls and webcasts. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the “Email Alerts” section of our investor relations page at ir.definitivehc.com.

Non-GAAP Financial Measures... (truncated) and accordingly may not be comparable to similarly titled measures used by other companies and are not measures of performance calculated in accordance with GAAP. Our presentation of these non-GAAP financial measures are intended as supplemental measures of our performance that are not required by, or presented in accordance with, GAAP. These non-GAAP financial measures should not be considered as alternatives to loss from operations, net loss, earnings per share, or any other performance measures derived in accordance with GAAP or as measures of operating cash flows or liquidity. A reconciliation of GAAP to non-GAAP results has been provided in the financial statement tables included at the end of this press release. In evaluating our non-GAAP financial measures, you should be aware that in the future, we may incur expenses similar to those eliminated in these presentations.

These non-GAAP financial measures are not required by or prepared in accordance with GAAP. These are supplemental financial measures of our performance and should not be considered substitutes for cash provided by operating activities, loss from operations, net loss, net income margin, gross profit, gross margin, or any other measure derived in accordance with GAAP.

Reconciliations to Certain Non-GAAP Measures

Unlevered Free Cash Flow

We define Unlevered Free Cash Flow as net cash provided by operating activities less purchases of property, equipment and data assets, plus cash interest expense, and cash payments related to transaction, integration, and restructuring related expenses, earnouts, and other non-core items paid in cash. Unlevered Free Cash Flow does not represent residual cash flow available for discretionary expenditures since, among other things, we have mandatory debt service requirements.

EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin

We define EBITDA as earnings before debt-related costs, including interest expense (income), net, and loss on partial extinguishment of debt, income taxes and depreciation and amortization. Adjusted EBITDA is defined as EBITDA adjusted to exclude certain items of a significant or unusual nature, including other income, net, equity-based compensation, transaction, integration, and restructuring expenses, goodwill impairments and other non-core expenses. Adjusted EBITDA Margin is defined as Adjusted EBITDA as a percentage of revenue. Adjusted EBITDA and Adjusted EBITDA Margin are key metrics used by management and our board of directors to assess the profitability of our operations. We believe that Adjusted EBITDA and Adjusted EBITDA Margin provide useful information to help investors to assess our operating performance because these metrics eliminate non-core and unusual items and non-cash expenses, which we do not consider indicative of ongoing operational performance. We believe that these metrics are helpful to investors in measuring the profitability of our operations on a consolidated level.

Adjusted Gross Profit and Adjusted Gross Margin

We define Adjusted Gross Profit as gross profit excluding acquisition-related amortization and equity-based compensation costs and Adjusted Gross Margin is defined as Adjusted Gross Profit as a percentage of revenue. Adjusted Gross Profit and Adjusted Gross Margin are key metrics used by management and our board of directors to assess our operations. We exclude acquisition-related depreciation and amortization expenses as they have no direct correlation to the cost of operating our business on an ongoing basis. A small portion of equity-based compensation is included in cost of revenue in accordance with GAAP but is excluded from our Adjusted Gross Profit calculations due to its non-cash nature.

Adjusted Operating Income

We define Adjusted Operating Income as loss from operations plus acquisition related amortization, equity-based compensation, transaction, integration, and restructuring expenses, goodwill impairments and other non-core expenses.

Adjusted Net Income and Adjusted Net Income Per Diluted Share

We define Adjusted Net Income as Adjusted Operating Income less interest expense net, recurring income tax (provision) benefit, foreign currency (loss) gain, and tax impacts of adjustments. We define Adjusted Net Income Per Diluted Share as Adjusted Net Income divided by diluted outstanding shares.

In evaluating our non-GAAP financial measures, you should be aware that in the future we may incur expenses similar to those eliminated in these presentations.

Investor Contact:

Brian Denyeau

ICR for Definitive Healthcare brian.denyeau@icrinc.com

646-277-1251

Media Contact:

Bethany Swackhamer bswackhamer@definitivehc.com

Definitive Healthcare Corp.

Reconciliations of Non-GAAP Financial Measures to Closest GAAP Equivalent

(d) Goodwill impairment represents non-cash, pre-tax, goodwill impairment charges. We experienced declines in our market capitalization as a result of sustained decreases in our stock price, which represented triggering events requiring our management to perform quantitative goodwill impairment tests as of the end of the first quarters of 2026 and 2025. As a result of the impairment tests conducted, we determined that the fair value of our single reporting unit was lower than its carrying value and, accordingly, recorded the impairment charges.... (truncated)n of strategic, financial, tax, and capital structure alternatives. Other non-core items also include consulting fees and severance costs associated with strategic transition initiatives, as well as other non-core items.

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.